How are ABBV strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ABBV strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 25.84%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$464.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a ABBV strangle?

The breakeven for the ABBV strangle priced on this page is roughly $195.36 and $224.65 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABBV market-implied 1-standard-deviation expected move is approximately 7.41%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current ABBV implied volatility affect this strangle?

ABBV ATM IV is at 25.84% with IV rank near 43.94%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

ABBV Strangle Strategy

ABBV (AbbVie Inc.), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NYSE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV (AbbVie Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $368.38B, a trailing P/E of 101.64, a beta of 0.31 versus the broader market, a 52-week range of 176.57-244.81, average daily share volume of 6.9M, a public-listing history dating back to 2013, approximately 55K full-time employees. These structural characteristics shape how ABBV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.31 indicates ABBV has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 101.64 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple. ABBV pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a strangle on ABBV?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current ABBV snapshot

As of May 15, 2026, spot at $210.80, ATM IV 25.84%, IV rank 43.94%, expected move 7.41%. The strangle on ABBV below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this strangle structure on ABBV specifically: ABBV IV at 25.84% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 7.41% (roughly $15.61 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABBV expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABBV should anchor to the underlying notional of $210.80 per share and to the trader's directional view on ABBV stock.

ABBV strangle setup

The ABBV strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABBV near $210.80, the first option leg uses a $220.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABBV chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABBV shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$220.00	$2.54
Buy 1	Put	$200.00	$2.11

ABBV strangle risk and reward

Net Premium / Debit: -$464.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$464.50
Breakeven(s): $195.36, $224.65
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

ABBV strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on ABBV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$19,534.50
$46.62	-77.9%	+$14,873.71
$93.23	-55.8%	+$10,212.91
$139.83	-33.7%	+$5,552.12
$186.44	-11.6%	+$891.32
$233.05	+10.6%	+$840.47
$279.66	+32.7%	+$5,501.26
$326.27	+54.8%	+$10,162.06
$372.87	+76.9%	+$14,822.85
$419.48	+99.0%	+$19,483.65

When traders use strangle on ABBV

Strangles on ABBV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABBV chain.

ABBV thesis for this strangle

The market-implied 1-standard-deviation range for ABBV extends from approximately $195.19 on the downside to $226.41 on the upside. A ABBV long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ABBV IV rank near 43.94% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on ABBV should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ABBV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABBV-specific events.

ABBV strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABBV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABBV alongside the broader basket even when ABBV-specific fundamentals are unchanged. Always rebuild the position from current ABBV chain quotes before placing a trade.

Frequently asked questions

What is a strangle on ABBV?: A strangle on ABBV is the strangle strategy applied to ABBV (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ABBV stock trading near $210.80, the strikes shown on this page are snapped to the nearest listed ABBV chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ABBV strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ABBV strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 25.84%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$464.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ABBV strangle?: The breakeven for the ABBV strangle priced on this page is roughly $195.36 and $224.65 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABBV market-implied 1-standard-deviation expected move is approximately 7.41%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on ABBV?: Strangles on ABBV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABBV chain.
How does current ABBV implied volatility affect this strangle?: ABBV ATM IV is at 25.84% with IV rank near 43.94%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.